Skip to main content
. 2022 May 24;25(4):573–586. doi: 10.1007/s11102-022-01229-9

Fig. 1.

Fig. 1

Schematic representation of the clinical courses for each of the thirteen patients prior to and following Met-PET. DA dopamine agonist, Met-PET/MRCR 11C-methionine PET coregistered with volumetric (FSPGR) MRI, PET Positron Emission Tomography, PRL prolactin, SRS stereotactic radiosurgery, TSS transsphenoidal surgery, ULN upper limit of normal